Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: docetaxel|DRUG: erlotinib hydrochloride
Sponsor: Paula Silverman, MD
Collaborators: National Cancer Institute (NCI)